The investment will be used to advance new treatments for limb-girdle and facioscapulohumeral muscular dystrophy, the company said. The series B funding round was led by Cambrian BioPharma. Vita Therapeutics has raised $66 million to date.
“The support from this strategic group of quality investors further validates Vita’s cell therapy platform and our mission to bring transformative therapies that target the root cause of disease to patients with muscle disorders and cancers,” Vita Therapeutics CEO Douglas Falk said in the Oct. 12 company news release.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
